Chemotherapy May Influence Esophageal Lugol Chromoendoscopy Severity: A Retrospective Cohort Study and Literature Review

ABSTRACT Lugol chromoendoscopy is widely used for screening esophageal squamous cell neoplasms (ESCNs) and evaluating dissection margins during endoscopic submucosal dissection (ESD). However, morphological variations may arise following treatment for synchronous cancers. This study aimed to assess...

Full description

Saved in:
Bibliographic Details
Published inThe Kaohsiung journal of medical sciences Vol. 41; no. 7; pp. e70020 - n/a
Main Authors Hsu, Wen‐Hung, Lin, Chien‐Chieh, Shih, Hsiang‐Yao, Chan, Leong‐Perng, Wang, Hui‐Ching, Chen, Yi‐Hsun, Hsu, Yu‐Chung, Hsieh, Hui‐Min, Wu, I‐Chen
Format Journal Article
LanguageEnglish
Published BP, Asia Wiley Publishing Asia Pty Ltd 01.07.2025
John Wiley & Sons, Inc
Wiley
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:ABSTRACT Lugol chromoendoscopy is widely used for screening esophageal squamous cell neoplasms (ESCNs) and evaluating dissection margins during endoscopic submucosal dissection (ESD). However, morphological variations may arise following treatment for synchronous cancers. This study aimed to assess the impact of chemotherapy on Lugol chromoendoscopy findings during both screening and ESD. From August 2009 to March 2024, ESCN patients undergoing esophageal ESD were enrolled. Lugol chromoendoscopy findings were analyzed based on four criteria: iodine staining, lesion size, margin assessment, and the pink‐color sign. Findings from screening endoscopy and ESD were compared, and medical records were reviewed for chemotherapy and radiation data. A literature review was also conducted to explore the potential effects of chemotherapy on Lugol chromoendoscopy findings. Among the 162 patients in this ESD cohort, 32 (19.8%) demonstrated notable differences between initial and follow‐up Lugol chromoendoscopy. Among them, 14 (43.8%) had undergone chemotherapy prior to ESD, while 26 received chemotherapy within 2 months before ESD. A significant proportion (53.8%) of chemotherapy‐treated patients exhibited faded chromoendoscopy findings (p < 0.01), despite no esophageal radiation exposure. Literature review findings supported our observation that chemotherapy may reduce Lugol voiding lesions. These findings suggest that chemotherapy influences lesion size and morphology during Lugol chromoendoscopy, underscoring the importance of careful timing and interpretation in these patients.
Bibliography:This work was supported by the National Science and Technology Council, NSTC 112‐2314‐B‐037‐084‐MY3; Kaohsiung Medical University, KMU‐TC114B04, KMU‐TB114004; Kaohsiung Medical University Chung‐Ho Memorial Hospital, KMUH113‐3R03, SI11312, KMUH‐DK(C)114008..
Funding
Correction added on 02 May 2025, after first online publication: Funding information is included in this version.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1607-551X
2410-8650
2410-8650
DOI:10.1002/kjm2.70020